David W. Cescon

Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer

Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working gr...